Clonazepam and sertraline: Absence of drug interaction in a multiple- dose study

Journal of Clinical Psychopharmacology

Volumn 20, Issue 1, 2000, Pages 19-27

  Bonate, Peter L ^a,d   Kroboth, Patricia D ^a   Smith, Randall B ^b,c   Suarez, Encarnacion ^c   Oo, Charles ^c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b Novum Pharmaceutical Research Services   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

^d SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

7 AMINOCLONAZEPAM; CLONAZEPAM; DRUG METABOLITE; PLACEBO; SERTRALINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; CROSSOVER PROCEDURE; DEPRESSION; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MIXTURE; FEMALE; HEADACHE; HUMAN; MALE; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; RANDOMIZED CONTROLLED TRIAL; SEDATION; VERTIGO;

ADULT; CLONAZEPAM; CROSS-OVER STUDIES; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; GABA MODULATORS; HUMANS; LINEAR MODELS; MALE; PLACEBOS; PSYCHOMOTOR PERFORMANCE; SEROTONIN UPTAKE INHIBITORS; SERTRALINE;

EID: 0033957228     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200002000-00005     Document Type: Article

References (33)

1. Smith WT, Londborg PD, Glaudin V, Painter JR. Clonazepam augmentation of fluoxetine in the treatment of outpatients with major depression: a double-blind, placebo-controlled, multicenter study. Psychopharmacol Bull 1996;32:519.
2. Lehtinen I, Lang AH, Jantti V, Keskinen E. Acute effects of alcohol on saccadic eye movements. Psychopharmacology (Berl) 1979;63:17-23.
3. Jenner P, Chadwick DW, Reynolds EH, Marsden CD. Altered 5-HT metabolism with clonazepam, diazepam, and diphenylhydantoin. J Pharm Pharmacol 1975;27:707-10.
4. Kishimoto Y, Kamata K, Sugihara T, Ishiguro S, Hazama H, Mizukawa R. Treatment of depression with clonazepam. Acta Psychiatr Scand 1988;77:81-6.
5. Chouinard G, Young SN, Annable L. Antimanic effect of clonazepam. Biol Psychiatry 1982;18:451-66.
6. Cohen LS, Rosenbaum JF. Clonazepam: new uses and potential problems. J Clin Psychiatry 1987;48:50-6.
7. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997;32:1-21.
8. Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 1996;31:444-69.
9. Harvey AT, Preskorn SH. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part I. J Clin Psychopharmacol 1996;16:273-85.
10. Ketter TA, Flockhart DA, Post RM, Denicoff K, Pazzaglia PJ, Marangell LB, George MS, Callan AM. The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol 1995;15:387-98.
11. Harvey AT, Preskorn SH. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part II. J Clin Psychopharmacol 1996;16:345-53.
12. Shader RI, von Moltke LL, Schmider J, Harmatz JS, Greenblatt DJ. The clinician and drug interactions: an update. J Clin Psychopharmacol 1996;16:197-201.
13. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996;153: 311-20.
14. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin reuptake inhibitors on cytochrome P450-2D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992;34:262-5.
15. Rasmussen BB, Maenpaa J, Pelkonen O, Loft S, Poulsen HE, Lykkesfeldt J, BrÌsen K. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol 1995;39:151-9.
16. Greenblatt DJ, von Moltke LL, Schmider J, Harmatz JS, Shader RI. Inhibition of human cytochrome P450-3A isoforms by fluoxetine and norfluoxetine: in vitro and in vivo studies. J Clin Pharmacol 1996;36:792-8.
17. von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 1995;15:125-31.
18. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Harmatz JS, Shader RI. Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole, and quinidine. Br J Clin Pharmacol 1994;38:23-31.
19. Seree E, Pisano PJ, Placidi M. Identification of the human and animal hepatic cytochrome P450 involved in clonazepam metabolism. Fundam Clin Pharmacol 1993;7:69-75.
20. Lai AA, Levy RH, Cutler RE. Time-course of interaction between carbamazepine and clonazepam in normal man. Clin Pharmacol Ther 1978;24:316-23.
21. Greenblatt DJ, Preskorn SH, Cotreau MM, Horst WD, Harmatz JS. Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther 1992;52:479-86.
22. von Moltke LL, Greenblatt DJ, Schmider J, Duan SX, Wright CE, Harmatz JS, Shader RI. Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol 1996;36:783-91.
23. Catterson ML, Preskorn SH. Pharmacokinetics of selective serotonin reuptake inhibitors: clinical relevance. Pharmacol Toxicol 1996;78:203-8.
24. Wechsler D. Wechsler-Adult Intelligence Scale-Revised (WAIS-R). San Antonio: The Psychological Corporation, 1981.
25. Swarbrick J, ed. Pharmacokinetics. New York: Marcel Dekker, Inc., 1982.
26. Lam FC, Hung CT, Perrier DG. Estimation of variance for harmonic mean half-lives. J Pharm Sci 1985;74:229-31.
27. SAS Institute. SAS/STAT user's guide, version 6. Cary, NC: SAS Institute, Inc., 1990.
28. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS, Shader RI. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J Pharmacol Exp Ther 1994;268:1278-83.
29. Ronfeld RA, Tremaine LM, Wilner KD. Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. Clin Pharmacokinet 1997;32:22-30.
30. Schmider J, Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI. N-demethylation of amitriptyline in vitro: role of cytochrome P-450 3A (CYP3A) isoforms and effect of metabolic inhibitors. J Pharmacol Exp Ther 1995;275:592-7.
31. Rapeport WG, Williams SA, Muirhead DC, Dewland PM, Tanner T, Wesnes K. Absence of a sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine. J Clin Psychiatry 1996;57:20-3.
32. Smith RB, Kroboth PD. Influence of dosing regimen on alprazolam and metabolite serum concentrations and tolerance to sedative and psychomotor effects. Psychopharmacology (Berl) 1987; 93:105-12.
33. Kroboth PD, Folan MM, Lush RM, Chaikin PC, Shukla UA, Barbhaiya R, Salazar DE. Coadministration of nefazodone and benzodiazepines: I. Pharmacodynamic assessment. J Clin Psychopharmacol 1995;15:306-19.